Survodutide: Complete Research Guide & Chemical Profile

Survodutide (BI 456906) is a potent dual glucagon receptor/GLP-1 receptor agonist developed through a collaboration between Zealand Pharma and Boehringer Ingelheim. This investigational acylated peptide is designed to simultaneously activate two metabolically important G-protein-coupled receptors — the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor (GCGR) — through a single molecular entity administered via once-weekly subcutaneous injection.

• Generic Name: Survodutide
• Development Code: BI 456906
• CAS Registry Number: 2805997-46-8
• Molecular Formula: C₁₉₂H₂₈₉N₄₇O₆₁
• Molecular Weight: 4,231.62 Da
• Classification: Synthetic acylated peptide, dual GLP-1/glucagon receptor agonist
• Peptide Length: 29 amino acid residues
• Administration Route (research): Subcutaneous injection, once weekly

Survodutide is a 29-amino-acid linear synthetic peptide based on the native glucagon sequence with strategic amino acid substitutions to introduce GLP-1 receptor cross-reactivity. The sequence begins with the non-coded amino acid 1-aminocyclobutane-1-carboxylic acid (Ac4c) at position 2, replacing the natural alanine residue. This substitution confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic cleavage while maintaining receptor binding affinity.

A critical structural modification is the C18 fatty diacid moiety conjugated at lysine-24 (Lys24) through a hydrophilic gamma-glutamic acid/mini-PEG linker. This lipidation enables reversible albumin binding, extending the circulating half-life to support once-weekly dosing. The C-terminus is amidated (-NH₂) for metabolic stability. The combination of the cyclobutane amino acid, specific substitutions at key positions, and the fatty acid acylation creates a molecule with defined dual-receptor engagement and favorable pharmacokinetic properties.

Survodutide activates both the GLP-1 receptor and the glucagon receptor, producing complementary metabolic effects. GLP-1 receptor agonism drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite regulation. Glucagon receptor agonism stimulates hepatic glycogenolysis, gluconeogenesis, amino acid catabolism, and — critically — activates thermogenic pathways that increase energy expenditure.

The dual-agonist hypothesis proposes that the glucagon receptor component provides metabolic benefits beyond those achievable with GLP-1 receptor agonism alone. Specifically, glucagon receptor activation promotes hepatic lipid oxidation, reduces hepatic de novo lipogenesis, and stimulates fibroblast growth factor 21 (FGF21) secretion. These hepatic effects make the dual GLP-1/glucagon mechanism particularly relevant to research on metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH).

Survodutide is engineered to achieve a specific ratio of glucagon-to-GLP-1 receptor activity. The molecule demonstrates potent agonism at both receptors, with the glucagon receptor component being a deliberate design feature rather than an undesirable side effect. This distinguishes it from selective GLP-1 receptor agonists (semaglutide, liraglutide) and from triple agonists (retatrutide, which adds GIP receptor activity).

• GLP-1 Receptor: Full agonist activity; drives insulin secretion, appetite suppression, and gastroparesis
• Glucagon Receptor: Significant agonist activity; promotes hepatic fat oxidation, thermogenesis, and energy expenditure
• GIP Receptor: No significant activity (distinguishes survodutide from tirzepatide and retatrutide)
• Design Rationale: The glucagon/GLP-1 balance is calibrated so that the insulinotropic and glucose-lowering effects of GLP-1R agonism counteract the hyperglycemic potential of glucagon receptor activation

Survodutide occupies a unique position in metabolic research as the most advanced dual GLP-1/glucagon receptor agonist in clinical development. Key areas of laboratory investigation include:

• MASH/Hepatic Steatosis Research: Investigating the mechanism by which dual GLP-1/glucagon agonism reduces hepatic lipid accumulation, resolves steatohepatitis, and reverses fibrosis in preclinical liver models.
• Hepatic Lipid Metabolism: Studying glucagon-mediated upregulation of fatty acid beta-oxidation, suppression of de novo lipogenesis, and FGF21 induction in hepatocyte cell lines and animal models.
• Energy Expenditure Pharmacology: Characterizing the thermogenic contribution of glucagon receptor agonism and its additive effects with GLP-1-mediated appetite suppression on total energy balance.
• Comparative Dual vs. Triple Agonism: Benchmarking survodutide (dual GLP-1/glucagon) against retatrutide (triple GLP-1/GIP/glucagon) to isolate the contribution of GIP receptor agonism.
• Fibrosis Biology: Examining the molecular mechanisms by which metabolic improvement through dual agonism translates to hepatic fibrosis regression.

Survodutide's pharmacokinetic profile is governed by its C18 fatty diacid acylation at Lys24, which enables high-affinity reversible binding to serum albumin. This albumin-binding mechanism creates a circulating depot that sustains plasma concentrations and supports once-weekly subcutaneous administration.

• Half-life: Approximately 5-7 days (enabling once-weekly administration)
• Absorption: Slow absorption from subcutaneous injection site; Tmax approximately 24-48 hours
• Protein Binding: >99% bound to serum albumin via C18 fatty acid chain
• Metabolism: Proteolytic degradation; the Ac4c at position 2 provides DPP-4 resistance
• Steady-State: Achieved after approximately 4-5 weekly administrations
• Dose Range (clinical studies): 0.6 mg to 6.0 mg subcutaneously, once weekly

Boehringer Ingelheim is evaluating survodutide across two major Phase 3 clinical programs: SYNCHRONIZE for obesity and LIVERAGE for MASH with fibrosis.

• SYNCHRONIZE-1: Phase 3 trial in adults with obesity without type 2 diabetes. Fully enrolled with 1,481 patients (combined SYNCHRONIZE-1 and -2). Phase 3 results expected in H1 2026.
• SYNCHRONIZE-2: Phase 3 trial in adults with obesity and type 2 diabetes. Evaluating multiple dose levels of survodutide vs. placebo.
• SYNCHRONIZE-CVOT: Cardiovascular outcomes trial designed to assess the effects of survodutide on major adverse cardiovascular events.
• LIVERAGE: Phase 3 program for MASH with fibrosis (stages F2-F3). Evaluating whether survodutide improves MASH histology and/or fibrosis after 52 weeks, and reduces end-stage liver disease outcomes over ~7 years.
• Phase 2 MASH Results (NEJM, 2024): Up to 83% of patients achieved ≥5% body weight loss; up to 62% achieved MASH resolution without worsening fibrosis; up to 52% achieved fibrosis improvement by at least one stage.

Survodutide shares storage requirements similar to other acylated peptides. The C18 fatty acid linkage, amidated C-terminus, and non-standard Ac4c residue each introduce specific stability considerations.

• Lyophilized Powder: Store at -20°C to -80°C under inert atmosphere (N₂ or Ar). Stable for 24+ months when properly desiccated.
• Reconstituted Solution: Store at 2-8°C. Use within 14-28 days. Bacteriostatic water preferred over sterile water for multi-use vials.
• Avoid Repeated Freeze-Thaw Cycles: Aliquot into single-use volumes. Each freeze-thaw cycle risks aggregation and loss of the fatty acid moiety.
• Light Protection: Store in amber vials. Aromatic residues (Trp, Phe, Tyr) are susceptible to photo-oxidation.
• pH Sensitivity: Optimal stability at pH 4.0-5.5. Alkaline conditions (pH >7.5) accelerate deamidation and hydrolysis.
• Temperature Excursions: Brief excursions to room temperature (≤30 minutes) during handling are acceptable; prolonged exposure to >25°C degrades the peptide.

Analytical characterization of survodutide requires methods capable of resolving the 29-residue acylated peptide and detecting degradation products including deacylated peptide, oxidized species, and deamidation products.

• RP-HPLC: C8 column with 300 Å pore size recommended for this acylated peptide. The C18 fatty acid chain increases hydrophobicity significantly; C18 columns may produce excessively long retention times. Purity threshold: ≥95% for research grade.
• LC-MS/MALDI-TOF: Confirm molecular weight of 4,231.62 Da. Key diagnostic peaks include the intact peptide, deacylated peptide (loss of ~340 Da fatty acid moiety), and oxidized species (+16 Da per methionine oxidation).
• Amino Acid Analysis: Verify composition, noting the non-standard Ac4c residue at position 2. This residue may not be detected by standard AAA methods and requires specialized protocols.
• Peptide Mapping: Enzymatic digestion (trypsin, Glu-C) followed by LC-MS/MS to confirm sequence integrity and Lys24-fatty acid conjugation.
• Size Exclusion Chromatography (SEC): Detect aggregation products, which are common degradation pathways for acylated peptides.
• Certificate of Analysis (CoA): Should include HPLC chromatogram, MS spectrum, amino acid analysis, net peptide content, and endotoxin levels.

As of April 2026, survodutide is in late-stage Phase 3 clinical development. The compound has received FDA Breakthrough Therapy designation for MASH with moderate or advanced fibrosis (F2-F3), European Medicines Agency PRIME scheme acceptance, and China NMPA Breakthrough Therapy designation. The Phase 2 MASH trial published in the New England Journal of Medicine (2024) demonstrated compelling hepatic endpoints that generated significant scientific interest.

The SYNCHRONIZE Phase 3 obesity trials and LIVERAGE Phase 3 MASH trials are fully enrolled with results expected in 2026. Regulatory approval is projected for 2027. Survodutide represents the most clinically advanced dual GLP-1/glucagon receptor agonist and a key research tool for understanding the metabolic benefits of combined GLP-1 and glucagon receptor engagement, particularly in the context of hepatic steatosis and fibrosis.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: TP508 (Chrysalin): Research Guide & Chemical Profile → https://www.chemverify.com/learn/tp508-chrysalin-research-guide-chemical-profile
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism